Abstract:Abstract Background: SUMOylation is a post-translational modification where small ubiquitin-like modifier (SUMO) proteins are conjugated to lysine residues of target proteins. SUMO proteins exist in all eukaryotes and participate in a catalytic cycle, which includes maturation, activation, conjugation, ligation, and de-modification. SUMOylation is known to regulate numerous molecular regulatory mechanisms such as: chromatin remodeling, DNA repair, immune responses, cell cycle progression, apoptosis, and the intracellular signal transduction. SUMOylation dysregulation is known to promote several diseases, including cancer cell survival. The unique traits of phenotypic and molecular adaptations found in naked mole rats (NMR) suggest high stability and effective functioning of the molecular machinery that counteract damage accumulation in its genome. NMR lifespan can reach up to 32 years and acquires a very efficient mechanism of resistance to cancer. This study aims to investigate the regulation of SUMO machinery between human cancer cells breast (MCF-7), colorectal (DLD-1), and neuroblastoma (SH-SY5Y)) and NMR brain and intestinal tissues, in order to find novel targets for cancer treatment. Results: The pairwise alignment identified the similarity of both SUMO genes and proteins including SUMO1, SUMO2/3, and SUMO components of Sentrin-specific protease isoforms (SENP 1-7), activation (SAE1 and Uba2), conjugation (Ubc9), and ligation isoforms (PIAS1-4) between NMR and human. In addition, qRT-PCR data revealed low expression of SUMO components at the mRNA level in NMR brain and intestinal tissues compared to MCF-7, DLD-1, and SH-SY5Y cell lines. On the contrary, PIAS4 expression is significantly higher in the NMR tissues compared to cancer cell lines. Protein analysis via Western blotting performed on MCF-7, DLD-1, and SH-SY5Y cell lines revealed similar levels to mRNA compared to NMR tissue. Ongoing studies are focusing on several functional assays to investigate effects of hUBE2I, hSENP1, and Myc/hPIAS4 effects on cytotoxicity and signaling properties of the cancer cells using techniques such as Microculture Tetrazolium (MTT), migration, invasion, and colony formation. The effect on cytotoxicity is also analyzed in relevance to clinical used treatments such as Doxorubicin in MCF-7, 5-Fluorouracil for DLD-1 and Methotrexate in SH-SY5Y. Conclusion: Expression analysis of SUMOylation machinery revealed lower expression of mRNA levels for SUMO components was observed in NMR tissues compared to all human cancer cells. However, PIAS4 expression was significantly higher in the NMR tissues compared to cancer cell lines. This data revealed important differences in NMR SUMOylation machinery (such as UBE2I, SENP1 and PIAS4) which provides a future therapeutic avenue to treat cancer. Citation Format: Mohammed Abdullah Mohammed Salih, Ritchie Williamson, Sriharsha Kantamneni. Elucidation of SUMOylation machinery in human cancer cells and naked mole-rat tissues [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 348.

Abstract 5393: Characterization of small ubiquitin-like modifier (SUMO) protein complex expression in human cancer cells to identify novel therapeutic targets

Abstract 348: Elucidation of SUMOylation machinery in human cancer cells and naked mole-rat tissues

SUMOylation Plays a Role in Gemcitabine- and Bortezomib-Induced Cytotoxicity in Human Oropharyngeal Carcinoma KB Gemcitabine-Resistant Clone.

SUMO and the robustness of cancer

Targeting SUMOylation dependency in human cancer stem cells through a unique SAE2 motif revealed by chemical genomics

Abstract 7071: Pharmacological targeting of SUMOylation leads to cBAF complex stabilization and disruption of the synovial sarcoma signature

Abstract 4538: Small Ubiquitin-Related Modifier-1 (SUMO-1) Modification of Retinoic Acid Receptor Α (rarα) Regulates Its Nuclear Localization and Metabolic Stability

Abstract 1098: Identification of SUMO2 as a novel therapeutic target for synovial sarcoma

Sumoylation As an Emerging Target in Therapeutics Against Cancer

Therapeutic Potential of Targeting the SUMO Pathway in Cancer

Abstract 6605: Understanding the role of sumoylated Etv1 in mammary oncogenesis

Sumoylation as an Emerging Target in Therapeutics against Cancer.

SUMOylation is Essential for Sirt2 Tumor-Suppressor Function in Neuroblastoma

The Emerging Roles of SUMOylation in the Tumor Microenvironment and Therapeutic Implications

NMR metabolomic profiling reveals new roles of SUMOylation in DNA damage response

The SUMO Family: Mechanisms and Implications in Thyroid Cancer Pathogenesis and Therapy

Inhibition of SUMOylation Induces Adaptive Antitumor Immunity against Pancreatic Cancer through Multiple Effects on the Tumor Microenvironment

Abstract 1642: NuMA exclusive post-translational modification in epithelial cancer cells is a novel target for cell eradication

Repression of the SUMO-conjugating enzyme UBC9 is associated with lowered double minutes and reduced tumor progression

Proteome-wide Analysis of SUMO2 Targets in Response to Pathological DNA Replication Stress in Human Cells.

Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer